Crinetics Pharmaceuticals Announces PALSONIFY Revenue and Positive Phase 2 Trial Results

Details

announced preliminary financial results for the fourth quarter of 2025, reporting over $5 million in net product revenue from PALSONIFY. Additionally, the company shared positive topline results from the fourth cohort of its Phase 2 trial for atumelnant, a treatment for congenital adrenal hyperplasia, showing significant reductions in androstenedione levels and glucocorticoid doses without serious adverse events.

Items reported

About Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of novel therapeutics for patients with endocrine conditions and other rare diseases. The primary focus of Crinetics is on crafting oral therapies that target hormone receptors, offering significant potential to transform the treatment landscape for several disorders. The company's pipeline includes investigational drugs such as paltusotine and CRN04894, aimed at addressing conditions like acromegaly and congenital adrenal hyperplasia, respectively. Crinetics combines cutting-edge drug discovery with an in-depth understanding of disease biology to impact the field of endocrinology substantially. By specializing in small molecules, Crinetics Pharmaceuticals seeks to provide new treatment options that enhance patient quality of life and address significant unmet medical needs. Headquartered in San Diego, California, the enterprise collaborates with academic institutions and industry partners to position its innovations at the forefront of medical advancement. Its work holds significant potential to influence the pharmaceutical industry, contributing to the expansion of targeted therapies within niche markets where few options currently exist.